CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Data collection from blood drawWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug440 CNS magnetic resonance imaging (MRI) imaging Wiki 1.00
drug723 Data collection from lumbar puncture Wiki 1.00
drug1489 Microscopy of defined brain regions on autopsy specimens Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D016638 Critical Illness NIH 0.14

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19

This study is to analyze the microglia reaction or direct neurotropic effects of CNS COVID-19 in pathogenesis and brain stem dysfunction in critically ill patients. A microglia-focused, brain-specific 50+ marker CODEX panel is used to assess the neuroinflammatory microenvironment in specific brain regions of deceased COVID-19 patients. The peripheral (cerebrospinal fluid and peripheral blood) cytokine response to SARS-CoV-2 is investigated in regard to CNS affection and consecutive blood brain barrier disruption leading to braininherent neuroinflammatory reactions

NCT04472013 COVID-19 Disease Other: Data collection from lumbar puncture Other: Data collection from blood draw Other: CNS magnetic resonance imaging (MRI) imaging Other: Microscopy of defined brain regions on autopsy specimens
MeSH:Critical Illness

Primary Outcomes

Description: Comparison of lesions from patients that are neurologically affected to non-affected individuals in terms of CNS involvement to describe encephalitic changes due to COVID-19 infection.

Measure: MRI imaging data

Time: Project duration for each patient takes 1 hour for the MRI at baseline

Description: Description of proteomic biomarkers (CSF and Plasma) in comparison with control reference sample.

Measure: Proteomic analysis

Time: 10 minutes for blood draw at baseline

Description: Mass cytometry will be performed form peripheral blood mononuclear cells to count cell population frequency.

Measure: Peripheral blood leukocyte Cytof Mass Cytometry Analysis for cell population frequency

Time: 10 minutes for blood draw at baseline

Description: In situ distribution assessment of marker expression (CD147 protein, ACE2 protein, Transmembrane protease serine subtype 2 (TMPRSS2))

Measure: CODEX (high dimensional microscopy) workflow analysis of defined regions on brain autopsy specimens

Time: at baseline


No related HPO nodes (Using clinical trials)